Ocean Biomedical Stock Current Asset
| OCEA Stock | 1.01 0.02 2.02% |
Ocean Biomedical fundamentals help investors to digest information that contributes to Ocean Biomedical's financial success or failures. It also enables traders to predict the movement of Ocean Stock. The fundamental analysis module provides a way to measure Ocean Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ocean Biomedical stock.
At present, Ocean Biomedical's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 565.1 K, whereas Other Current Assets are forecasted to decline to about 76.7 K. Ocean | Current Asset |
Ocean Biomedical Company Current Asset Analysis
Ocean Biomedical's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Ocean Current Asset Historical Pattern
Today, most investors in Ocean Biomedical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ocean Biomedical's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Ocean Biomedical current asset as a starting point in their analysis.
Ocean Biomedical Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Ocean Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Ocean Biomedical has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and about the same as Health Care (which currently averages 0.0) industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Ocean Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ocean Biomedical's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ocean Biomedical could also be used in its relative valuation, which is a method of valuing Ocean Biomedical by comparing valuation metrics of similar companies.Ocean Biomedical is currently under evaluation in current asset category among its peers.
Ocean Fundamentals
| Return On Asset | -6.82 | ||||
| Current Valuation | 49.44 M | ||||
| Shares Outstanding | 34.65 M | ||||
| Shares Owned By Insiders | 71.98 % | ||||
| Shares Owned By Institutions | 11.62 % | ||||
| Number Of Shares Shorted | 183.68 K | ||||
| Price To Book | 100.67 X | ||||
| EBITDA | (957.74 K) | ||||
| Net Income | (958.43 K) | ||||
| Total Debt | 2.15 M | ||||
| Book Value Per Share | (2.21) X | ||||
| Cash Flow From Operations | (747.3 K) | ||||
| Short Ratio | 4.31 X | ||||
| Earnings Per Share | (2.75) X | ||||
| Target Price | 18.5 | ||||
| Beta | 1.51 | ||||
| Market Capitalization | 34.3 M | ||||
| Total Asset | 110.91 M | ||||
| Retained Earnings | (2.77 M) | ||||
| Working Capital | (3 M) | ||||
| Net Asset | 110.91 M |
About Ocean Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ocean Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocean Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocean Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| AVAV | AeroVironment | |
| ELVN | Enliven Therapeutics | |
| NFLX | Netflix |
Check out Ocean Biomedical Piotroski F Score and Ocean Biomedical Altman Z Score analysis. For information on how to trade Ocean Stock refer to our How to Trade Ocean Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocean Biomedical. If investors know Ocean will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocean Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.75) | Return On Assets (6.82) |
The market value of Ocean Biomedical is measured differently than its book value, which is the value of Ocean that is recorded on the company's balance sheet. Investors also form their own opinion of Ocean Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Ocean Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocean Biomedical's market value can be influenced by many factors that don't directly affect Ocean Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocean Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocean Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocean Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.